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ARTICLE HIGHLIGHTS: 5 
Type of Research:  Single Center, Retrospective, Non-Randomized Cohort study. 6 
Key Findings:  Seventy-one COVID-19 patients had 107 venous duplex examination studies. 7 
Presence of DVT was noted in 37 % of examinations. Majority of those who experienced DVT 8 
were male (67%) with proximal DVT and had a significantly elevated mean d-dimer (5447 9 
ng/ml), Alkaline Phosphatase (Alk Po4, 110 IU/L). A d-dimer cutoff 2450 ng/ml provided a 70% 10 
and 59.5% sensitivity and specificity.  11 
Take home Message: A model for calculating the probability of DVT in patients with severe 12 
COVID-19 can be developed that may help identify risk for DVT.  13 
Based on our results, patients may need a higher dose of anticoagulation therapy as most of our 14 
patients diagnosed with DVT while on anticoagulation.  15 
Table of Contents Summary: 16 
Single Center, retrospective, non-randomized study investigating the relationship of COVID-19 17 
and   deep venous thrombosis (DVT). Seventy-one COVID-19 patients had 107 venous duplex 18 
examination studies with DVT noted in 37% of the examinations. The majority were male (67%) 19 
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with elevated d-dimer (mean,5447 ng/ml). Males with severe infection were at highest risk of 1 









Abstract:  11 
Objective: Early reports suggest that patients with COVID-19 infection carry a significant risk 12 
of altered coagulation with an increased risk for venous thromboembolic events. This report 13 
investigates the relationship of significant COVID-19 infection and deep venous thrombosis 14 
(DVT) as reflected in the patient clinical/laboratory characteristics.  15 
Methods: We reviewed demographics, clinical presentation, laboratory/radiological evaluations, 16 
results of venous duplex imaging and mortality of COVID-19 positive patients (18-89 years) 17 
admitted to the Indiana University Academic Health Center. Using oxygen saturation, 18 
radiological findings and need for advanced respiratory therapies; patients were classified into 19 
4 
 
mild, moderate or severe categories of COVID-19 infection. Descriptive analysis was performed 1 
using univariate and bivariate Fisher’s exact and Wilcoxon rank-sum tests to examine the 2 
distribution of patient characteristics and compare the DVT outcomes. A multivariable logistic 3 
regression model was used to estimate the Adjusted Odds Ratio of experiencing DVT while a   4 
Receiver Operating Curve (ROC)analysis to identify the optimal cutoff for d-dimer to predict 5 
DVT in this COVID-19 cohort. Time to the diagnosis of DVT from admission was analyzed 6 
using log-rank test and Kaplan Meier plots.  7 
Results: Our study included 71 unique COVID-19 positive patients (mean age 61 years) 8 
categorized as having 3% mild, 14% moderate and 83% severe infection and evaluated with 107 9 
venous duplex studies. DVT was identified in 47.8% of patients (37% examinations) at an 10 
average of 5.9 days post admission. Patients with DVT were predominantly male (67%, p 11 
=0.032) with proximal venous involvement. (29% upper and 39% in the lower extremities with 12 
55% of the latter demonstrating bilateral  involvement).  Patients with DVT had a significantly 13 
higher mean d-dimer  of 5447 ng/ml (SD 7032, p=0.0101), and Alkaline Phosphatase (Alk Po4) 14 
of 110 IU/L (p=0.0095) than those without DVT.  On multivariable analysis, elevated d-dimer 15 
(p=0.038) & Alk Po4 (p=0.021) were associated with risk for DVT while age, gender, elevated 16 
CRP and ferritin levels were not. ROC analysis suggests an optimal d-dimer value of 2450 ng/ml 17 
cutoff with 70% sensitivity, 59.5% specificity, and 61% positive and 68.8% negative predictive 18 
values. 19 
Conclusion: This study suggests that males with severe COVID-19 infection requiring 20 
hospitalization are at highest risk for developing DVT. Elevated d-dimers, Alk Po4 along with 21 
our multivariable model can alert the clinician to the increased risk of DVT requiring early 22 
evaluation and aggressive treatment 23 
5 
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Introduction:  3 
SARS-COV2 otherwise also known as COVID-19 is an infection due to a Novel Corona Virus-4 
19. COVID-19 can present in mild, moderate or severe forms 1,2. Patients who are admitted to 5 
either an inpatient facility or to an intensive care unit tend to have moderate to severe symptoms 6 
with shortness of breath progressing to pneumonia requiring supportive respiratory therapy with 7 
or without the need for multi organ supportive therapy 3. In a small number of patients, COVID-8 
19 infection leads to cytokine surge, endothelial dysfunction with an increase in acute phase 9 
reactants and inflammatory markers resulting in coagulopathy. Increases in d-Dimer, fibrinogen, 10 
C-reactive protein and ferritin levels indicate the combination of a prothrombotic and hyper-11 
inflammatory state that may contribute to COVID-19 associated severity of illness, morbidity 12 
and mortality 4-7  13 
The objective of our report is to examine the select group of patients who were admitted to 14 
hospital with COVID-19 infection and had venous duplex ultrasonography imaging. We report 15 
their characteristics in the context of clinical severity and   laboratory results.  This report 16 
examines mortality outcome and comparisons between the two cohorts of patients who were 17 
positive for COVID-19 but differed in the presence or absence of DVT. 18 
Methods: The study was conducted in accordance with the Declaration of Helsinki. The study 19 
was granted expedited review status by Indiana University School of Medicine -Institutional 20 
Review Board (IRB Protocol 2004249979). 21 
Study Cohort:  22 
7 
 
All COVID-19 positive patients between age group of 18 to 89 years admitted to the Academic 1 
Health Center, Indiana University Health and who had a duplex examination of their venous 2 
system between March 15th and April 14th, 2020 were included in this study. These patients were 3 
admitted to either an inpatient or intensive care unit of the hospital depending on the level of the 4 
care required. Study patients were identified from In Record Time (In Record Time, LLC. 5 
Fenton, Michigan), our vascular lab database that records and maintains every non-invasive 6 
vascular imaging and interpretation in the facility. Appropriate annotation of COVID-19 status 7 
was made in the vascular database. 8 
Patient & Laboratory Characteristics :Patient demographics consisted of age, gender, race, 9 
insurance status , body mass index (BMI), smoking status, renal function with need for  renal 10 
replacement therapy, history of active or remote cancer, use of immune suppression medications, 11 
and history of any organ or hematopoietic transplantation  were identified from patients records. 12 
Patients were classified as mild or moderate severity of infection depending on < or > 94% 13 
Oxygen Saturation respectively. Severe category patients had in addition respiratory rate of >30, 14 
PaO2/FiO2 ≤ 300 mmHg or need for Mechanical Ventilation.  Using medications charted in 15 
Cerner, the hospital electronic medical records, documentation was made of the use of 16 
angiotensin converting enzyme (ACE) inhibitors or angiotensin Receptor blockers (ARB), use 17 
and type of anticoagulation, hydroxychloroquine, antiviral medications per hospital protocol ( 18 
Remdesivir, Lopinavir, Ritonavir) used in treatment. Laboratory variables  in terms of serum 19 
hemoglobin in gm% (Hb%), hematocrit (Hct), C-reactive protein in mg/L (CRP), erythrocyte 20 
sedimentation rate mm/Hour (ESR), Platelet (Plt)  per microliter, serum fibrinogen levels in 21 
mg/dl (fibrinogen), d-dimer in ng/ml, renal function test with blood Urea nitrogen (BUN), serum 22 
creatinine in mg/dl, liver function test results with aspartate aminotransferase (AST) Units/L) , 23 
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alanine aminotransferase (ALT Units/L),  alkaline phosphatase (Alk Po4 IU/L), serum ferritin in 1 
ng/ml, serum. Procalcitonin in ng/ml, and presence or absence of any abnormality on 2 
electrocardiography (EKG) were recorded. For the purposes of reporting the severity of COVID-3 
19 infection and medication usage, they were recorded either less than or equal to  48 hours from 4 
the day of the venous duplex examination. 5 
 Venous Duplex Examinations:  All patients had either upper and/or lower extremity venous 6 
duplex ultrasonography at the request of the treating physicians. Patients had imaging of either 7 
one or all four extremities.  Patients were then categorized into two groups depending on the 8 
status of the venous duplex examination as either positive or negative for deep venous 9 
thrombosis (DVT). Extent (proximal versus distal) as well as the location (superficial venous 10 
thrombosis (SVT) and/or DVT) of the venous thrombus was considered for reporting. Time to 11 
diagnosis of the venous thrombosis from the time of admission was recorded using the admission 12 
date. All examinations were carried out by registered vascular technologists and interpreted by 13 
attending physicians in accordance with the protocols suggested by the Intersocietal 14 
Accreditation Commission (IAC)   15 
Statistical Analysis: All the above-mentioned variables including the venous duplex 16 
examination results were entered into the REDCap  database for analysis. REDCap ( Research 17 
Electronic Data Capture ) is a Health Insurance Portability and Accountability Act (HIPAA) 18 
compliant , highly secure and intuitive tool designed by Vanderbilt University, USA used by the 19 
participating institutions in developing databases to capture data for clinical and translational 20 
research.8 . Descriptive analysis was performed to examine the distribution of patient 21 
characteristics and DVT outcomes in the COVID-19 positive patients using frequency 22 
distribution for categorical variables and mean (standard deviation, SD) and median (inter-23 
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quartile range IQR) for continuous variables. Bivariate analyses were conducted to investigate 1 
the socio-demographic, clinical and laboratory characteristics of patients with COVID-19 2 
infection and the incidence of DVT using Fisher’s exact test and Wilcoxon rank-sum test for 3 
categorical and continuous variables, respectively. Multivariable logistic regression was used to 4 
examine the Adjusted Odds Ratio (AOR) of DVT with 95% Confidence intervals (CI) of the 5 
AOR among COVID patients. The coefficients from the multivariable logistic model were  used 6 
to define an equation to obtain the probability of developing DVT in male and female patients 7 
separately. Mathematically, the logistic regression model can be presented as 
()
	()
=  +8 
. , which can be used to obtain probability or risk that an outcome=1 by using the formula 9 
 (.)
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, where exp is the natural exponential function,  is the logistic regression 10 
coefficient and x is the covariate in the model.. All variables with p<0.20 in the bivariate analysis 11 
and those with p>0.20 ( age, S.ferritin ) otherwise considered clinically important were included 12 
in multivariable analysis Multicollinearity was assessed and any potential variables with variance 13 
inflation greater than 10 were excluded from the multivariable modeling. The multivariable 14 
model included gender, age, d-dimer, CRP, ferritin, and Alk Po4. Time to diagnosis of DVT 15 
from admission was analyzed using log-rank test to determine the time-to-event differences 16 
between different severity levels of COVID-19 and was displayed using Kaplan Meier plots. 17 
Receiver Operating Curve (ROC) analysis for d-dimer as a predictor of DVT was done to report 18 
the Area Under the Curve (AUC). Youden Index was used to identify the optimal cutoff for the 19 
d-dimer that would distinguish between DVT positive and DVT negative cases. Sensitivity, 20 
specificity, positive predictive value (PPV) and negative predictive values (NPV) were reported 21 
for different levels of the cutoff based on an increment of 500 ng/ml. All analyses were 22 
performed at 0.05 level of significance using Stata SE/14.2 (StataCorp, L.P., and College Station, 23 
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TX).  1 
Results: This study includes 71 unique COVID-19 positive patients, who underwent 107 venous 2 
duplex examinations between March 15th to April 14th, 2020 at the Academic Health Center, 3 
Indiana University School of Medicine (IU-AHC). Mean age of the cohort were 61 years (± 4 
14.56) with a majority male (54%) and African American patients (61%).  Forty two percent of 5 
our patients were either ex-smokers or active smokers at the time of admission. Only 10% of the 6 
patients were uninsured. The majority of our patients were categorized into severe COVID-19 7 
infections (83%) while 17% were with moderate (14%) to mild (2.8%) infections. Patient’s 8 
demographics, comorbidities, use of medications was compared between the two patient groups 9 
consisting of those with or without any form of thrombotic event in the venous system. Among 10 
the 34 patients (48%) who had a positive venous duplex examination, we observed 23 patients 11 
were males (68%) (p= 0.032) and race was not found to be significant (p=0.329) for venous 12 
thrombotic events. Additional results are shown in Table 1. 13 
Bi-variate analysis (Online table 1) evaluating the use of ACE (p= 0.665), ARB (p=0.599), 14 
hydroxychloroquine (p>0.99), hypoglycemic agents (p=0.315), statins (p >0.99) and antiviral 15 
medications (p=0.479) demonstrated no difference between groups. The majority of patients 16 
(99%) were on anticoagulation (84% on prophylactic and 16% on therapeutic dose) with either 17 
Unfractionated Heparin (UFH) or Low Molecular Weight Heparin (LMWH) at the time of DVT 18 
diagnosis. In the cohort of patients with DVT, laboratory levels of d-dimers (p=0.010),Alk Po4 19 
(p=0.009) were found to be abnormally elevated and statistically significant while CRP 20 
(p=0.077) , AST (p=0.060) trended towards significance  on bivariate analysis  between those 21 
with and without DVT. Table 2 provides additional information on   laboratory parameters in 22 
patients with and without DVT.  23 
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There were no significant differences identified in abnormal chest x rays (p>0.99) in those 1 
patients (N=68) where the information was available. EKG changes with QT prolongation was 2 
see in 6 patients with no differences between the groups with and without DVT (p >0.99, 3 3 
patients in each group). 4 
Positive findings on the venous duplex examination for DVT were found  in 37% (N=40) 5 
examinations. Patients had venous thrombotic events, either in isolation or in combination with a 6 
proximal or distal venous system in the upper and/or lower extremities. The majority of the 7 
venous duplex examinations included an evaluation of the lower extremities (70/107 exams). 8 
Fifty five percent of all the positive lower extremity examinations had a positive finding for 9 
venous thrombotic event in both lower extremities while 29% of the upper extremity venous 10 
examinations had a positive finding in both upper extremities. Proximal venous thrombosis was 11 
found in 39% of lower extremity examinations in the femoral and popliteal veins with 29% of 12 
upper extremity examinations having venous thrombosis in the proximal venous system 13 
including one or more of the brachial, axillary and subclavian veins. Isolated SVT was found in 14 
17. 8% (N=19) examinations. SVT was most frequently found in the upper extremities, 54% of 15 
patients, and in association with proximal deep venous thrombosis. Details of venous thrombotic 16 
events are shown in Online table 2. There was no statistical difference in the probability of 17 
being diagnosed with  DVT among moderate and severe COVID-19 cases (p=0.197), however 18 
the time to event analysis by severity of COVID-19 symptoms using   Kaplan Meier plot shows 19 
(Figure:  1) that the likelihood of  diagnosis of  DVT for severe category of COVID-19 patients 20 
was higher and trending towards significance as was seen in the univariate Cox regression 21 
(HR=2.13, 95% CI: 0.64, 7.08) than that for mild to moderate patients. On an average, the days 22 
from admission to the diagnosis of DVT was 10.4 days for mild/moderate and 6.83 days for 23 
12 
 
severe COVID-19 patients. This difference was not statistically significant as analyzed by 1 
Wilcoxon rank sum test (p-value=0.9416).   2 
Based on the (ROC) analysis (Figure:2A), the sensitivity, specificity and predictive values of d-3 
dimers at 500 ng/ml units’ intervals was analyzed and obtained an optimal cutoff of  2450 ng/ml.  4 
This cutoff was also validated using Youden Index after ROC analysis. Table 3 shows d-dimer 5 
levels in increments of 500 ng/ml along with their specificity %, sensitivity %, PPV %and NPV 6 
%. At 2450 ng/ml, these values are 70.6%, 59.5%, 61.5% and 68.8% respectively  7 
Our multivariable logistic regression model (Figure:2B) for predicting the odds of DVT gave us 8 
an AUC of 0.8214 which indicates that the model has a good predictive ability¹¹ and potential of 9 
clinical utility to discriminate DVT cases from non-DVT cases among COVID-19 patients. 10 
Table 4 shows patient and laboratory characteristics with the adjusted odds ratio predicting their 11 
association with DVT amongst COVID-19 patients.  Elevated d-dimers (p=0.038) and Alk Po4 12 
(p=0.021) were significantly associated with the risk of diagnosing DVT.  Based on this model, 13 
we propose equations for the probability of DVT occurrences in COVID-19 positive patients 14 
among male and female cases is as shown below.  15 
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Similarly, for male COVID-19 positive patients the probability for DVT can be predicted by 17 
using  18 
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Here, e represents the natural exponential function, -2.672 is a constant in the logistic regression, 1 
and 0.0002, -0.0013, 0.0004, 0.0269, -0.0042, and -1.2947 are the coefficients respectively for 2 
the variables d-dimer, CRP, Ferritin, AlkPO4, Age and Female.  3 
Mechanical ventilation were required in 77.5% patients in the entire cohort with 3 patients 4 
required ECMO. There were no differences in the use of either mechanical ventilation or ECMO 5 
in patients with and without DVT. 6 
In this entire cohort, ten deaths (14%) occurred during the follow-up period of 13.4 ±7.1 days. 7 
All deaths were related to progressive sepsis with multi-organ dysfunction. The analysis of 8 
survival comparing the mild/moderate disease and severe disease patients did not reach statistical 9 
significance.  10 
Discussion: At the time of this manuscript the United States accounted for both the highest 11 
number of patients as well as fatalities due to COVID-19 infections in the world   We had a 12 
mortality of 14 % in our cohort which is similar to those reported for all COVID-19 related 13 
admissions to Intensive care units requiring advanced respiratory therapies and supportive care.9-14 
12  . Our results demonstrate similar observations with significant number of male COVID-19 15 
positive patients with others reporting a high BMI as an additional risk.13,14. Similar to published 16 
reports our cohort is composed of approximately 60% African American patients. 15.  17 
Similar to our results, venous thromboembolism (VTE) in critically ill patients with COVID-19 18 
reportedly ranges from 25-31%.16-18 Patients with severe and fatal COVID-19 are in a 19 
prothrombotic and hyper-inflammatory state with reportedly higher d-dimer levels 4-6,18,21-23. 20 
Given the varying degrees of  sensitivity ( 80-100% ) , specificity (23-63% ) d-dimer levels  are 21 
not advised as a single definitive test for  diagnosis 19-20 for VTE.Tang et al  defined the high risk 22 
14 
 
population as having a D-dimer elevation more than six times the upper limit of normal and 1 
Sepsis Induced Coagulopathy (SIC) score of more than or equal to 4 .16. In our study, the 2 
sensitivity of d-dimer of 2450g/ml was approximately 70% and specificity was approximately 3 
60% and reflect the limitations of using d-dimer as a stand-alone trigger for treatment.  It also 4 
must be noted that 99% of our patients were on anticoagulation (84% on prophylactic and 16% 5 
on therapeutic dose) at the time of diagnosis. Given the high percentage of patients who were 6 
diagnosed with DVT while on prophylactic anticoagulation, one might postulate that these 7 
patients need full anticoagulation to be reliably protected against experiencing DVT.   8 
 Mechanisms related to such high levels of d-dimer as well as the  risk of DVT may be related to 9 
a cytokine surge, the upregulation of hypoxia induced transcription pathways 16, or potentially 10 
the  use of continuous positive airway pressure (c-PAP) ventilator, thought to  compress 11 
superficial or deep vessels of the upper limbs which might lead to thrombosis24 . Our study 12 
provides no insights into the underlying pathophysiology. 13 
 14 
The presence of liver abnormalities have been observed in the COVID population potentially due 15 
to various pathophysiological pathways.25 Worsening transaminases such as, Alk-Po4 a sign of 16 
significant liver disease, is associated with heightened risk of VTE.  based on our analysis. Cui et 17 
al 17 has suggested worsening transaminases is related to worse patient outcomes in COVID-19.  18 
Chen et al 26 similarly suggest an aspartate aminotransferase >40U/liter (HR: 2.2, 95% CI: 1.1- 19 
6.73) was an independent risk factor associated with fatal outcome.  20 
Based on our multivariable analysis, d-dimer along with C- reactive protein, alkaline 21 
phosphatase, ferritin levels and gender would be helpful to assess the probability of underlying 22 
deep venous thrombosis. An absolute level of D dimer cannot be used to initiate a high dose 23 
15 
 
anticoagulation in COVID-19 positive patients, we recommend calculating the probability of 1 
venous thromboembolism in these patients and then make decisions based on clinical needs of 2 
the patient.  This model should help guide further treatment decisions. A larger cohort is needed 3 
to validate our observations.  4 
Similar to sepsis induced coagulopathy, there are reports that suggest survival benefit in COIVD-5 
19 patients with pneumonia and DVT when treated with anticoagulation 16,26 .  Available 6 
algorithms   take into consideration Well’s pretest probability score 28,29 advising either 7 
prophylaxis, thrombostabilizing protocol, or therapeutic anticoagulation for DVT and PE.  8 
However, given the limitations  30-31 with varying degrees of sensitivity, specificity as well as age 9 
related challenges and ability to predict only the proximal venous thrombosis, it remains to be 10 
seen if the Well’s score can be used to advise anticoagulation strategies for COVID-19 patients. 11 
To overcome some of these limitations age adjusted d-dimer along with Well’s probability score 12 
32 has been advised.  13 
Based on initial observations, which forms the basis for this report, a high dose anticoagulant 14 
regimen was advised for DVT prophylaxis (Online table 3) in our health facility for ICU 15 
COVID-19 patients.  Since both upper and lower extremities are often involved with DVT in our 16 
cohort, there appears to be little role for IVC filters in this patient population. Relatively low 17 
sensitivity of D-dimer amidst high DVT prevalence warrants consideration of empiric 18 
anticoagulation on admission. If the probability score is high based on our multivariate model, 19 
we postulate that patients will benefit a therapeutic dose to offer protection against DVT. Our 20 
observations are similar to Obi et al indicating H1N1 ARDS patients had 23.3-fold higher risk 21 
for pulmonary embolism and 17.9-fold increased risk for VTE. This led to authors concluding 22 
16 
 
empirical systemic heparin anticoagulation in this cohort of patients significantly reduced VTE 1 
incidence without increased hemorrhagic complications 33 2 
Given the concerns for acquiring COVID-19 infection   and to protect our health care providers, 3 
prudent and judicious use of the vascular lab resources is critical.  Since anticoagulation will be 4 
provided no matter where the DVT is found, termination of extensive testing seems warranted 5 
when a major proximal DVT is found. In addition to the concerns expressed by Obi et al 28 we 6 
believe that an algorithm of who is at most risk based on gender and other factors from our 7 
multivariate model might eventually provide an answer on whom to study.   8 
 This report focuses on patients in the moderate to severe categories of COVID-19 infection 9 
requiring hospital admission. This study adds to the existing body of literature in that male 10 
patients are at highest risk for complications. The study has strengths in the fact that all patients 11 
included in the study had a venous duplex ultrasonography to provide confirmation of DVT. We 12 
have identified variables beyond those described to predict the probability of DVT in patients 13 
with COVID-19 infection. Besides a small sample size, weakness of the study is very similar to 14 
those inherent to any single center retrospective series and, limited by inherent biases related to 15 
patient selection, investigation, as well as treatments provided. The multivariable model 16 
proposed in this manuscript needs further validation and research. In addition, the study has also 17 
its weakness as we did not perform evaluations for the pulmonary embolism or investigating for 18 
the caval or iliac venous thrombosis.  19 
  20 
 21 
Conclusions:   22 
17 
 
 Male gender and patients admitted with severe category of COVID-19 infections are at high risk 1 
for DVT.  Elevated d-dimer and Alk Po4 levels have the ability to predict DVT in our model.  2 
Our novel multivariate predictive model should provide guidance, as we consider high dose 3 
empiric anticoagulation in this high risk COVID-19 patients. To limit the risk of exposure to 4 
healthcare workers considerations should be given in judicious ordering of vascular lab imaging.  5 
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Table 1 : Patient Characteristics and bivariate relationship with DVT 
Characteristics In Sample (n=71) DVT status p-value 
 Negative (n=37) Positive (n=34) 
Age (n=71)      0.7478 
Mean (SD) 61.06 (14.56) 61.11 (13.6) 61 (15.74)  
Median (IQR) 63 (20) 63 (14) 65 (20)  
Gender      0.032 
Male 38 (54%) 15 ((41%) 23 (68%)  
Female 33 (46%) 22 (59%) 11 (32%)  
Race      0.329 
Whites 22 (31%) 13 (35%) 9 ((27%)  
AA 43 (61%) 23 (62%) 20 (61%)  
Others 5 (7%) 1 (3%) 4 (12%)  
  Missing  1 (1%)      
     
Smoking Status      0.934 
Current Smokers 6 (8%) 3 (8%) 3 (10%)  
Former Smokers 24 (34%) 14 (38%) 10 ((32%)  
Never Smokers 38 (54%) 20 (54%) 18 (58%)  
    Missing  3(4%)      
     
Active Cancer      >0.99 
No 65 (92%) 35 (95%) 30 (94%)  
Yes 4 (6%) 2 (5%) 2 (6%)  
Missing 2 (2%)      
Remote Cancer      >0.99 
No 64 (90%) 34 (92%) 30 (94%)  
Yes 5 ((7%) 3 (8%) 2 (6%)  
Missing 2 (3%)      
Insurance       0.442 
Medicare 33 (46%) 19 (51%) 14 (41%)  
Medicaid 7 (10%) 5 (14%) 2 (6%)  
Private 22 (31%) 10 (27%) 12 (35%)  
Others 2 (3%) 0 (0) 2 (6%)  
Uninsured 7 (10%) 3 (8%) 4 (12%)  
CKD      0.088 
No 55 (78%) 26 (70%) 29 (88%)  
Yes 15 (21%) 11 (30%) 4 (12%)  
Missing 1 (1%)      
RRT (Renal 
Replacement therapy) 
     0.479 
No 70 (99%) 37 (100) 33 (97%)  
Yes 1 (1%) 0 (0) 1 (3%)  
      0.152 
Immune Sup Med      >0.99 
No 63  33 (89%) 30 (91%)  
Yes 7  4 (11%) 3 (9%)  
Missing 1       
HTN      0.795 
No 21 (30%) 10 (27%) 11 (32%)  
Yes 50 (70%) 27 (73%) 23 (68%)  
CAD      >0.99 
No 54 (76%) 28 (76%) 26 (76%)  
Yes 17 (24%) 9 (24%) 8 (24%)  
Diabetes      0.628 
No 43 (61%) 21 (57%) 22 (65%)  
Yes 28 (39%) 16 (43%) 12 (35%)  
Hyperlipidemia      0.232 
No 35 (49%) 21 (58%) 14 (42%)  
Yes 34 (48%) 15 (42%) 19 (58%)  
Missing 2 (3%)      
COPD      >0.99 
No 64 (90%) 33 (89%) 31 (91%)  
Yes 7 (10%) 4 (11%) 3 (9%)  
BMI (n=70)      0.4727 
Mean (SD) 33.62 (8.35) 34.61 (9.12) 32.54 (7.4)  
Median (IQR) 33 (10.2) 33 (12.9) 31 (8.9)  
COVID Severity       0.867 
Mild 2 (3%) 1 (3%) 1 (3%)  
Moderate 10 (14%) 6 (16%) 4 (12%)  
Severe 59 (83%) 30 (81%) 29 (85%)  




Table 2: Bivariate Analysis of Lab Parameters comparing patients with and without Deep venous 
Thrombosis  
Lab Parameters (In Sample) Results  
Mean (SD) 
DVT Negative  
Mean (SD) 
DVT Positive  
Mean (SD) 
P Value  
Hgb  gm% (n=71) 10.72 (1.99) 10.47 (1.94) 11 (2.05) 0.4038 
HCT (n=71) 32.48 (5.99) 31.78 (5.8) 33.25 (6.18) 0.4878 
d-dimer ng/ml (n=67) 3941.21 
(5240.36) 
2644.03 (2378.77) 5447.61 
(7032.01) 
0.0101 
Fibrinogen mg/dl (n=41) 664.66 (198.69) 655.57 (220.84) 676.28 (171.8) 0.8422 
Platelets /microlit (n=71) 282.76 (98.91) 290.73 (107.67) 274.09 (89.2) 0.5313 
CRP mg/L(n=67) 18.26 (17.35) 17.54 (21.83) 19.1 (10.26) 0.0772 
ESR (n=11) 80.82 (25.33) 83 (31.84) 79 (21.51) 0.9361 
Ferritin ng/ml (n=65) 1038.73 
(1191.61) 
820.83 (1001.94) 1277.7 (1346.15) 0.1295 
Procalcitonin ng/ml (n=29) 2.18 (5.92) 2.38 (7.7) 1.94 (2.72) 0.1873 
BUN mg/dl (n=70) 32.86 (25.95) 35.94 (28.67) 29.59 (22.7) 0.2841 
Serum Creatinine 
mg/dl(n=70) 
1.41 (1.65) 1.57 (1.91) 1.25 (1.32) 0.3222 
Albumin mg/dl (n=68) 2.91 (0.58) 2.9 (0.44) 2.91 (0.71) 0.4015 
AST Units /L (n=68) 59.16 (47.49) 47.72 (36.17) 72.03 (55.44) 0.0604 
ALT Units/L (n=68) 50.49 (40.31) 45.25 (34.69) 56.38 (45.67) 0.3828 
















Table 3: Optimal cutoff of d-dimer values to predict DVT in patients with COVID-19 infection 
d-dimer ng/ml 
Cutoff 




PPV, % NPV, % 
1450 47.9 0.63 85.3 40.5 56.9 75 
1950 47.9 0.64 76.5 51.4 59.1 70.4 
2450* 47.9 0.65 70.6 59.5 61.5 68.8 
2950 47.9 0.6 58.8 62.2 58.8 62.2 
3450 47.9 0.63 55.9 70.3 63.3 63.4 
3950 47.9 0.59 44.1 73 60 58.7 
       























Table 4 : Multivariable Analysis of DVT among COVID positive patients  
Characteristics Adj. Odds 
Ratio 
95% CI p-value 
d-dimer 1.000243 1.000014 1.000472 0.038 
CRP 0.9987068 0.9600632 1.038906 0.949 
ferritin 1.000353 0.999747 1.000959 0.254 
alkpo4 1.027308 1.003987 1.05117 0.021 
Age 0.9958539 0.9517951 1.041952 0.857 




















Online Table 1 : Bivariate Analysis of patient’s medications and status of deep venous 
thrombosis 




DVT Positive ( 
N=34)  
P Value 
Aspirin      0.315 
No 47 (66.2) 22 (59.46) 25 (73.53)  
Yes 24 (33.8) 15 (40.54) 9 (26.47)  
ACE      0.665 
No 66 (92.96) 35 (94.59) 31 (91.18)  
Yes 5 (7.04) 2 (5.41) 3 (8.82)  
ARB      0.599 
No 67 (94.37) 36 (97.3) 31 (93.94)  
Yes 3 (4.23) 1 (2.7) 2 (6.06)  
Missing 1 (1.41)    
Hydroxychloroquine      >0.99 
No 28 (39.44) 15 (40.54) 13 (38.24)  
Yes 43 (60.56) 22 (59.46) 21 (61.76)  
Hypoglycemics      0.315 
No 46 (64.79) 22 (59.46) 24 (72.73)  
Yes 24 (33.8) 15 (40.54) 9 (27.27)  
Missing 1 (1.41)    
Statins      >0.99 
No 50 (70.42) 26 (70.27) 24 (70.59)  
Yes 21 (29.58) 11 (29.73) 10 (29.41)  
Antiviral Medications      0.479 
No 61 (85.92) 30 (83.33) 31 (91.18)  
Yes 9 (12.68) 6 (16.67) 3 (8.82)  
Missing 1 (1.41)    
Anticoagulation 
Status at the time of 
Diagnosis  
     >0.99 
No 1 (1.41) 1 (2.7) 0 (0)  
Yes 70 (98.59) 36 (97.3) 34 (100)  
If Yes, Types      0.515 
Therapeutic 11 (15.71) 7 (19.44) 4 (11.76)  






Online Table 2: Description of location and extent of venous thrombotic events  
Location and Extent of Venous Thrombosis (N=107 Examinations: 70 
Lower extremity+37 Upper extremity  ) 
% Positive Studies  
Total number of venous thrombotic events  55% (N=59 ) 
Total number of Deep venous thrombosis (DVT) 37.38% (N=40) 
Total number of isolated Superficial venous Thrombosis   17.75% ( N=19 ) 
Bilateral Lower extremity DVT (of lower extremity examinations) 55%  
Bilateral Upper extremity DVT ( of upper extremity examinations) 29% 
 % Positive Proximal DVT in lower extremity examinations  ( 
Femoral , Popliteal Veins)  
39% 
 % Positive Proximal DVT in upper extremity examinations ( 

















Online table 3 : Indiana University –Academic Health Center Protocol for Prophylactic dosing of 
anticoagulation in severe COVID-19 infections . 
Creatinine Clearance  Weight - < 119kg Weight 120-150kg Weight > 150kg 






< 30ml/min, End 
stage renal disease 
Heparin 5000Q8H Heparin 7500Q8H Heparin 7500Q8H 
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